Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 23

1.

The newer Opioid Agonist Treatment with lower substitutive opiate doses is associated with better toxicology outcome than the older Harm Reduction Treatment.

Bizzarri JV, Casetti V, Sanna L, Maremmani AG, Rovai L, Bacciardi S, Piacentino D, Conca A, Maremmani I.

Ann Gen Psychiatry. 2016 Nov 25;15:34. eCollection 2016 Nov 25. Erratum in: Ann Gen Psychiatry. 2017 Feb 13;16:10.

2.

Association between cannabis use and treatment outcomes in patients receiving methadone maintenance treatment: a systematic review protocol.

Zielinski L, Bhatt M, Eisen RB, Perera S, Bhatnagar N, MacKillop J, Steiner M, McDermid Vaz S, Thabane L, Samaan Z.

Syst Rev. 2016 Aug 16;5(1):139. doi: 10.1186/s13643-016-0317-2.

3.

Correlates of Nine-Month Retention following Interim Buprenorphine-Naloxone Treatment in Opioid Dependence: A Pilot Study.

HÃ¥kansson A, Widinghoff C, Abrahamsson T, Gedeon C.

J Addict. 2016;2016:6487217. doi: 10.1155/2016/6487217. Epub 2016 Jan 21.

4.

The effects of dronabinol during detoxification and the initiation of treatment with extended release naltrexone.

Bisaga A, Sullivan MA, Glass A, Mishlen K, Pavlicova M, Haney M, Raby WN, Levin FR, Carpenter KM, Mariani JJ, Nunes EV.

Drug Alcohol Depend. 2015 Sep 1;154:38-45. doi: 10.1016/j.drugalcdep.2015.05.013. Epub 2015 Jul 8.

5.

Marijuana use and achievement of abstinence from alcohol and other drugs among people with substance dependence: a prospective cohort study.

Mojarrad M, Samet JH, Cheng DM, Winter MR, Saitz R.

Drug Alcohol Depend. 2014 Sep 1;142:91-7. doi: 10.1016/j.drugalcdep.2014.06.006. Epub 2014 Jun 18.

6.

Methadone treatment in Iranian opiate addicts: a preliminary report.

Eslami Shahrbabaki M, Ziaaddini H, Hagh Doost AA, Ghasemi M, Eslami Shahrbabaki P, Alizadeh Nouri R, Eslami Shahrbabaki N.

Addict Health. 2011 Winter-Spring;3(1-2):53-60.

7.

Treatment retention among patients randomized to buprenorphine/naloxone compared to methadone in a multi-site trial.

Hser YI, Saxon AJ, Huang D, Hasson A, Thomas C, Hillhouse M, Jacobs P, Teruya C, McLaughlin P, Wiest K, Cohen A, Ling W.

Addiction. 2014 Jan;109(1):79-87. doi: 10.1111/add.12333. Epub 2013 Oct 9.

8.

Impact of cannabis use during stabilization on methadone maintenance treatment.

Scavone JL, Sterling RC, Weinstein SP, Van Bockstaele EJ.

Am J Addict. 2013 Jul-Aug;22(4):344-51. doi: 10.1111/j.1521-0391.2013.12044.x.

9.

Cannabinoid and opioid interactions: implications for opiate dependence and withdrawal.

Scavone JL, Sterling RC, Van Bockstaele EJ.

Neuroscience. 2013 Sep 17;248:637-54. doi: 10.1016/j.neuroscience.2013.04.034. Epub 2013 Apr 24. Review.

10.

Association of cannabis use with opioid outcomes among opioid-dependent youth.

Hill KP, Bennett HE, Griffin ML, Connery HS, Fitzmaurice GM, Subramaniam G, Woody GE, Weiss RD.

Drug Alcohol Depend. 2013 Sep 1;132(1-2):342-5. doi: 10.1016/j.drugalcdep.2013.02.030. Epub 2013 Mar 22.

11.

Superior methadone treatment outcome in Hmong compared with non-Hmong patients.

Bart G, Wang Q, Hodges JS, Nolan C, Carlson G.

J Subst Abuse Treat. 2012 Oct;43(3):269-75. doi: 10.1016/j.jsat.2011.12.006. Epub 2012 Jan 28.

12.

Association between use of specific drugs and antiretroviral adherence: findings from MACH 14.

Rosen MI, Black AC, Arnsten JH, Goggin K, Remien RH, Simoni JM, Golin CE, Bangsberg DR, Liu H.

AIDS Behav. 2013 Jan;17(1):142-7. doi: 10.1007/s10461-011-0124-7.

13.

Contingency management is efficacious and improves outcomes in cocaine patients with pretreatment marijuana use.

Alessi SM, Rash C, Petry NM.

Drug Alcohol Depend. 2011 Oct 1;118(1):62-7. doi: 10.1016/j.drugalcdep.2011.03.001. Epub 2011 Mar 26.

14.

Reduced cannabis use after low-dose naltrexone addition to opioid detoxification.

Mannelli P, Peindl K, Patkar AA, Wu LT, Pae CU, Gorelick DA.

J Clin Psychopharmacol. 2010 Aug;30(4):476-8. doi: 10.1097/JCP.0b013e3181e5c168. No abstract available.

15.

Pharmacotherapy in the treatment of addiction: methadone.

Kreek MJ, Borg L, Ducat E, Ray B.

J Addict Dis. 2010 Apr;29(2):200-16. doi: 10.1080/10550881003684798.

16.

Intermittent marijuana use is associated with improved retention in naltrexone treatment for opiate-dependence.

Raby WN, Carpenter KM, Rothenberg J, Brooks AC, Jiang H, Sullivan M, Bisaga A, Comer S, Nunes EV.

Am J Addict. 2009 Jul-Aug;18(4):301-8. doi: 10.1080/10550490902927785.

17.

Correlates of stimulant treatment outcome across treatment modalities.

Peirce JM, Petry NM, Roll JM, Kolodner K, Krasnansky J, Stabile PQ, Brown C, Stitzer ML.

Am J Drug Alcohol Abuse. 2009;35(1):48-53. doi: 10.1080/00952990802455444.

18.
19.

Heroin transition risk among daily and non-daily cannabis users who are non-injectors of heroin.

Valdez A, Cepeda A, Neaigus A, Russell A.

Int J Drug Policy. 2008 Dec;19(6):442-9. doi: 10.1016/j.drugpo.2007.06.004. Epub 2007 Aug 6.

20.

Self-report of illicit benzodiazepine use on the Addiction Severity Index predicts treatment outcome.

Ghitza UE, Epstein DH, Preston KL.

Drug Alcohol Depend. 2008 Sep 1;97(1-2):150-7. doi: 10.1016/j.drugalcdep.2008.04.003. Epub 2008 May 21.

Supplemental Content

Support Center